PALISADE BIO, INC.
PALISADE BIO, INC. (PALI): 1 pipeline candidate · ~102 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
102.4 months
D/E 0.05 · 25% dilution
Lead: Phase 1
1 candidate
N/A
2 buys · 2 sells (180d)
A transparent, data-derived signal for PALISADE BIO, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$294.6M
Cash
$132.6M
Quarterly Burn
$3.9M
Runway
102.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| pali-2108 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
93
Total value held
$246.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 21,378,904 | $37.5M |
| perceptive advisors llc | 17,856,298 | $31.2M |
| ameriprise financial inc | 8,711,385 | $15.2M |
| commodore capital lp | 7,181,062 | $12.6M |
| ra capital management, l.p. | 7,124,116 | $12.5M |
| franklin resources inc | 5,785,189 | $10.1M |
| goldman sachs group inc | 5,373,951 | $9.4M |
| boxer capital management, llc | 4,799,875 | $8.4M |
| morgan stanley | 4,551,533 | $8.0M |
| adage capital partners gp, l.l.c. | 4,500,000 | $7.9M |
Showing top 10 of 93 institutional holders of PALISADE BIO, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PALISADE BIO, INC.'s pipeline?
PALISADE BIO, INC. (PALI) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is PALISADE BIO, INC.'s lead drug candidate?
PALISADE BIO, INC.'s most advanced tracked candidate is pali-2108 (Phase 1) for Fibrostenotic Crohn's Disease; Ulcerative Colitis (UC).
What is PALISADE BIO, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PALISADE BIO, INC. has approximately 102.4 months of cash runway.
What is PALISADE BIO, INC.'s market capitalization?
PALISADE BIO, INC.'s market capitalization is approximately $294.6M.
Who is the CEO of PALISADE BIO, INC.?
Mr. J. D. Finley is the chief executive officer of PALISADE BIO, INC. (PALI).
Get the full picture on PALISADE BIO, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.